Microenvironment and Immunology Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis Jelena Stanisavljevic 1 , Jordina Loubat-Casanovas 1 , Mercedes Herrera 2 , Tomas Luque 3,4 , Ra ul Pe ~ na 1 , Ana Lluch 5,6 , Joan Albanell 7,8,9 ,Felix Bonilla 2 , Ana Rovira 7,8 , Cristina Pe ~ na 2 , Daniel Navajas 3,4,12 , Federico Rojo 7,10,11 , Antonio García de Herreros 1,9 , and Josep Baulida 1 Abstract Crosstalk between tumor and stromal cells in the tumor micro- environment alter its properties in ways that facilitate the invasive behavior of tumor cells. Here, we demonstrate that cancer-asso- ciated broblasts (CAF) increase the stiffness of the extracellular matrix (ECM) and promote anisotropic ber orientation, two mechanical signals generated through a Snail1/RhoA/aSMA dependent mechanism that sustains oriented tumor cell migra- tion and invasiveness. Snail1-depleted CAF failed to acquire myobroblastic traits in response to TGFb, including RhoA acti- vation, aSMA-positive stress bers, increased bronectin brillo- genesis, and production of a stiff ECM with oriented bers. Snail1 expression in human tumorderived CAF was associated with an ability to organize the ECM. In coculture, a relatively smaller number of Snail1-expressing CAF were capable of imposing an anisotropic ECM architecture, compared with nonactivated bro- blasts. Pathologically, human breast cancers with Snail1 þ CAF tended to exhibit desmoplastic areas with anisotropic bers, lymph node involvement, and poorer outcomes. Snail1 involve- ment in driving an ordered ECM was further conrmed in wound- healing experiments in mice, with Snail1 depletion preventing the anisotropic organization of granulation tissue and delaying wound healing. Overall, our results showed that inhibiting Snail1 function in CAF could prevent tumor-driven ECM reorganization and cancer invasion. Cancer Res; 75(2); 28495. Ó2014 AACR. Introduction Myobroblasts are activated broblasts that remodel connec- tive tissues in processes, such as development and wound healing (1, 2). They typically contain contractile aSMA (smooth muscle alpha actin)-positive stress bers linked to and required for the formation of supermature integrin focal contacts, named bro- nexus. Fibronexus transmits intracellular tensional forces to extra- cellular bronectin molecules, allowing their assemblage into bers (3). Extracellular bronectin bers facilitate and guide the polymerization of other molecules, such as thrombospondin-1, perostin, tenascin C (4), brillin, and collagen (5), into the extracellular matrix (ECM). aSMA-positive stress bers also connect intercellular cadherin junctions that permit them to withstand mechanical stress between neighbor cells; indeed, adherens junctions of cultured myobroblasts are signicantly larger than those of aSMA-neg- ative broblasts (6). The ECM architecture of connective tissues and the myobroblast phenotype, including nuclei (7) and cell shapes (3), ultimately depend on an intraextracellular tensional dialog mediated by these specialized cellsubstrate and cellcell structures. Cancer-associated broblasts (CAF) are a heterogeneous population of activated broblasts whose activity in the stroma associates with tumor progression and malignancy. CAFs pro- duce paracrine growth factors, proteolytic enzymes, and ECM components, and contribute to generate a desmoplastic response (brillar network deposition) around cancer cells (8) similar to that at the granulation tissue of wounds. Thus, CAF activity perturbs not only the biochemical but also the biomechanical homeostasis of the tumor microenvironment; these perturbances are sensed by tumor cells and ultimately affect their behavior (9). In breast cancer, mechanical proper- ties of the stroma, such as stiffness (10) and ber alignment (11), force progression of the disease. In fact, the presence of dense and aligned collagen bers around human breast carci- nomas is a prognostic signature for poor survival (12, 13). CAFs are permanently activated by a TGFb autocrine loop (14), and 1 Programa de Recerca en Cancer, Institut Hospital del Mar d'Investiga- cions Mediques, Barcelona, Spain. 2 Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Majadahonda, Madrid, Spain. 3 Unitat de Biofísica i Bioenginyeria, Universitat de Barcelona, Barcelona, Spain. 4 Institute for Bioengineering of Catalo- nia, Barcelona, Spain. 5 Department of Oncology and Hematology, Hospital Clínico Universitario, Valencia, Spain. 6 Department of Medi- cine, Valencia Central University, Valencia, Spain. 7 Molecular Thera- peutics and Biomarkers in Cancer Laboratory, Institut Hospital del Mar d'Investigacions Mediques, Hospital del Mar, Barcelona, Spain. 8 Med- ical Oncology Department, Hospital del Mar, Barcelona, Spain. 9 Depar- tament de Ci encies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. 10 Department of Pathology, IIS-Fundaci on Jimenez Díaz, Madrid, Spain. 11 Department of Pathology, Hospital del Mar, Barcelona, Spain. 12 Ciber Enfermedades Respiratorias (CIBERES), 07110-Bunyola, Spain. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). Corresponding Author: Josep Baulida, IMIM, C/Dr. Aiguader, 88, 08003, Bar- celona, Spain. Phone: 34-3-316-0436; Fax: 34-3-316-0410. E-mail: jbaulida@imim.es doi: 10.1158/0008-5472.CAN-14-1903 Ó2014 American Association for Cancer Research. Cancer Research Cancer Res; 75(2) January 15, 2015 284 on April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1903